Immunology and Infectious Diseases Department, Great Ormond Street Hospital for Children, London, United Kingdom.
Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Front Immunol. 2022 May 30;13:881259. doi: 10.3389/fimmu.2022.881259. eCollection 2022.
Critical respiratory manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are rare in children, and little is known about how immunocompromised children respond to the infection. We report a case of a 4-year-old boy with activated PI3K delta syndrome type 2 (APDS2) with a protracted and severe COVID-19 course with both inflammatory and acute respiratory features. He was treated with remdesivir, nitazoxanide, high-dose corticosteroids, and tocilizumab and made a full recovery. We propose that remdesivir may be used in combination with nitazoxanide to improve viral clearance and reduce the chance of resistance in treating acute SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的严重呼吸道表现在儿童中较为罕见,关于免疫功能低下的儿童如何感染该病毒知之甚少。我们报告了一例 4 岁男孩,患有活化的 PI3Kδ 综合征 2 型(APDS2),其 COVID-19 病程迁延且严重,具有炎症和急性呼吸特征。他接受了瑞德西韦、硝唑尼特、大剂量皮质类固醇和托珠单抗治疗,并完全康复。我们提出,瑞德西韦可能与硝唑尼特联合使用,以提高病毒清除率并降低治疗急性 SARS-CoV-2 感染的耐药机会。